Carpe diem: What mergers can do for you
This is a fantastic piece in Nature by Anu Acharya, CEO of Ocimum Biosolutions in India. I recommend reading the article in full. A few key points that struck us…
Menu
Update: Pain continues to be painful
This week we learn that two novel pain medications will never see the light of day: Novartis had reached the market with the COX-II inhibitor Prexige (rebranded as the unusually…
BioTrinity Panel Discussions
We regret that we were unable to attend the panel discussions at BioTrinity last week. However, an excellent summary was posted on the PharmaPhorum web site. Of note: 1. Investment…
Report on BioTrinity Partnering, April 12-14
Last week, Lacerta Bio attended the annual BioTrinity Partnering and Investment Conference in Newbury, UK. This was our first time at this conference. So how was the conference? A few…
VCs Abandoning Biotech for the Web?
Fred Frank, a highly respected investment banker, greeted us on Tuesday morning with this missive: Venture capitalists, who make high-risk investments in start-ups, are tired of waiting years for biotech companies…